Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches

Core Insights - Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, will present new data on multiple hematologic malignancies at the American Society of Hematology (ASH) Annual Meeting from December 6-9 [1] - The data will emphasize Merck's commitment to advancing clinical research in hematology and its diverse pipeline of investigational candidates [1] Company Focus - Merck is actively involved in clinical research related to hematologic malignancies, showcasing its expanding pipeline of investigational candidates [1] - The presentation at ASH reflects the company's ongoing efforts to contribute to advancements in the field of hematology [1]